Page 4 - 2021 Spring CMTA Report - Special Research Edition
P. 4
BUILDING
AND PAYING
FOR A STAR
When CMTA Board Chair Gilles Bouchard started getting involved
with the organization 11 years ago, he found the world of CMT
research depressing: Some great researchers were working
on CMT, but because there were no pharmaceutical companies
involved, the research wasn’t being translated to treatments.
$17 MILLION
SINCE 2008
Research tools for
biotech companies
More than 30 of the leading CMT
scientists and gene therapy experts Investments in the discovery of new geneS
50 active research
projects
19 joint preclinical treatment studies
4
